The U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) in combination with chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting.
This approval marks the first and only immunotherapy-based treatment for use before surgery for NSCLC.